ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

ME Staff 8-k
-
0

ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 2.04. Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

The disclosure set forth in Item 8.01 of this Current Report on Form8-K is incorporated herein by reference.

Item 8.01. Other Events.

On June22, 2018 (the “Redemption Date”), Abbott Laboratories (the “Company”) redeemed $1,300,000,000 of the $1,795,500,000 outstanding aggregate principal amount of its 2.350% Notes due 2019 (the “Notes”), issued to that certain Indenture, dated as of March10, 2015, between the Company, as issuer, and U.S. Bank National Association, as trustee, as amended and supplemented by that certain Officers’ Certificate to Sections 3.1 and 3.3 of the Indenture, dated as of November22, 2016 (collectively, the “Indenture”), in accordance with the terms of the Indenture. The Company redeemed the Notes at a redemption price equal to 100.000% of the aggregate principal amount of such Notes redeemed, plus accrued and unpaid interest thereon to, but excluding, the Redemption Date. The partial redemption of the Notes resulted in $495,500,000 aggregate principal amount of Notes remaining outstanding.


About ABBOTT LABORATORIES (NYSE:ABT)

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.